The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1284
Diclofenac Gel For Osteoarthritis
The full article is available to subscribers Subscriber Login   

The nonsteroidal anti-inflammatory drug (NSAID) diclofenac, has been approved by the FDA in a 1% topical gel formulation (Voltaren Gel – Endo) for treatment of osteoarthritis (OA). A 3% topical diclofenac gel (Solaraze) is currently approved for treatment of actinic keratoses,1 but not for topical use on joints. No other topical NSAIDs are approved by the FDA for OA. A diclofenac patch (Flector) was recently approved by the FDA for treatment of pain due to minor strains, sprains and contusions.2

CLINICAL STUDIES — An eight-week randomized double-blind trial in 385 patients with symptomatic OA of the hand found topical diclofenac gel 2 g applied four times daily more effective in controlling pain than its vehicle alone; after 6 weeks, pain scores were reduced by 46% with the gel, compared to 36% with the vehicle alone, which was ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Diclofenac Gel For Osteoarthritis
Article code: 1284b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian